Skip to main content
Erschienen in: InFo Neurologie + Psychiatrie 5/2019

20.05.2019 | Apoplex | aktuell

Neuro-Update-Seminar 2019

Die wichtigsten neueren Studien in der Neurologie kompakt aufbereitet

verfasst von: Kathrin von Kieseritzky, Dr. med Katharina Geschke, Dr. med. Kirsten Westphal

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Beim Neuro-Update-Seminar am 5. und 6. April in Berlin präsentierten namhafte Experten — wie schon zwei Wochen zuvor in Mainz — die wichtigsten Studienergebnisse des vergangenen Jahres in kompakter Form. Das bewährte Format fand dieses Jahr bereits zum elften Mal statt. Lesen Sie ausgewählte Highlights zu Fortschritten in den Indikationen Multiple Sklerose, Morbus Parkinson, Migräne sowie akuter Schlaganfall.
Literatur
1.
Zurück zum Zitat Jelcic I et al. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell 2018; 175(1):85–100.e23 CrossRef Jelcic I et al. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell 2018; 175(1):85–100.e23 CrossRef
2.
Zurück zum Zitat Barro C et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 2018; 141(8):2382–91 CrossRef Barro C et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 2018; 141(8):2382–91 CrossRef
4.
Zurück zum Zitat Chitnis T et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric multiple sclerosis. N Engl J Med 2018; 379:1017–26 Chitnis T et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric multiple sclerosis. N Engl J Med 2018; 379:1017–26
Zurück zum Zitat Vortrag „MS/Neuroimmunologie“ (Volker Limmroth). Neuro-Update 2019, Berlin, 5.–6.4.2019 Vortrag „MS/Neuroimmunologie“ (Volker Limmroth). Neuro-Update 2019, Berlin, 5.–6.4.2019
1.
Zurück zum Zitat Killinger BA et al. The vermiform appendix impacts the risk of developing Parkinson’s disease. Sci Transl Med 2018; 10:1–5 CrossRef Killinger BA et al. The vermiform appendix impacts the risk of developing Parkinson’s disease. Sci Transl Med 2018; 10:1–5 CrossRef
2.
Zurück zum Zitat Jankovic J et al. Safety and Tolerability of multiple ascending doses of PRX002/RG7935, an anti-?-synuclein monoclonal antibody, in patients with Parkinson disease. JAMA Neurology 2018; 75(10):1206–14 CrossRef Jankovic J et al. Safety and Tolerability of multiple ascending doses of PRX002/RG7935, an anti-?-synuclein monoclonal antibody, in patients with Parkinson disease. JAMA Neurology 2018; 75(10):1206–14 CrossRef
3.
Zurück zum Zitat Fujimaki M et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 2018; 90:e404–11 CrossRef Fujimaki M et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 2018; 90:e404–11 CrossRef
4.
Zurück zum Zitat Bang-Hoon C et al. Association of coffee consumption and nonmotor symptoms in drug-naïve, early-stage Parkinson’s disease. Parkinsonism and Related Disorders 2018; 50:42–7 CrossRef Bang-Hoon C et al. Association of coffee consumption and nonmotor symptoms in drug-naïve, early-stage Parkinson’s disease. Parkinsonism and Related Disorders 2018; 50:42–7 CrossRef
5.
Zurück zum Zitat Ferreira JJ et al. Effectiveness of Opicapone and switching from Entacapone in fluctuating Parkinson disease. Neurology 2018: e1849–57 Ferreira JJ et al. Effectiveness of Opicapone and switching from Entacapone in fluctuating Parkinson disease. Neurology 2018: e1849–57
Zurück zum Zitat Vortrag „Bewegungsstörungen“ (Heinz Reichmann). Neuro-Update 2019, Berlin, 5.–6.4.2019 Vortrag „Bewegungsstörungen“ (Heinz Reichmann). Neuro-Update 2019, Berlin, 5.–6.4.2019
2.
Zurück zum Zitat Dodick DW et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018; 38(6):1026–37. CrossRef Dodick DW et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018; 38(6):1026–37. CrossRef
3.
Zurück zum Zitat Reuter U et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom twoto-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018; 392(10161):2280–7. CrossRef Reuter U et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom twoto-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018; 392(10161):2280–7. CrossRef
4.
Zurück zum Zitat Dodick DW et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018; 319(19):1999–2008. CrossRef Dodick DW et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018; 319(19):1999–2008. CrossRef
5.
Zurück zum Zitat Skljarevski V et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018; 38(8):1442–54. CrossRef Skljarevski V et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018; 38(8):1442–54. CrossRef
Zurück zum Zitat Vortrag „Schmerz/Kopfschmerz“ (Christian Maihöfner). Neuro-Update 2019, Berlin, 5.–6.4.2019 Vortrag „Schmerz/Kopfschmerz“ (Christian Maihöfner). Neuro-Update 2019, Berlin, 5.–6.4.2019
1.
Zurück zum Zitat Thomalla G et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018;379(7):611–22 CrossRef Thomalla G et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018;379(7):611–22 CrossRef
2.
Zurück zum Zitat Pihlasviita S et al. Diagnosing cerebral ischemia with door-to-thrombolysis times below 20 minutes. Neurology. 2018;91(6):e498–e508 CrossRef Pihlasviita S et al. Diagnosing cerebral ischemia with door-to-thrombolysis times below 20 minutes. Neurology. 2018;91(6):e498–e508 CrossRef
3.
Zurück zum Zitat Schultheiss M et al. Intravenous thrombolysis in acute central retinal artery occlusion - A prospective interventional case series. PLoS One. 2018;13(5):e0198114 CrossRef Schultheiss M et al. Intravenous thrombolysis in acute central retinal artery occlusion - A prospective interventional case series. PLoS One. 2018;13(5):e0198114 CrossRef
Zurück zum Zitat Vortrag „Schlaganfall akut“ (Joachim Röther). Neuro-Update 2019, Berlin, 5.–6.4.2019 Vortrag „Schlaganfall akut“ (Joachim Röther). Neuro-Update 2019, Berlin, 5.–6.4.2019
Metadaten
Titel
Neuro-Update-Seminar 2019
Die wichtigsten neueren Studien in der Neurologie kompakt aufbereitet
verfasst von
Kathrin von Kieseritzky
Dr. med Katharina Geschke
Dr. med. Kirsten Westphal
Publikationsdatum
20.05.2019
Verlag
Springer Medizin
Erschienen in
InFo Neurologie + Psychiatrie / Ausgabe 5/2019
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI
https://doi.org/10.1007/s15005-019-0085-3

Weitere Artikel der Ausgabe 5/2019

InFo Neurologie + Psychiatrie 5/2019 Zur Ausgabe